JPH11511961A - 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 - Google Patents
組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用Info
- Publication number
- JPH11511961A JPH11511961A JP9500280A JP50028097A JPH11511961A JP H11511961 A JPH11511961 A JP H11511961A JP 9500280 A JP9500280 A JP 9500280A JP 50028097 A JP50028097 A JP 50028097A JP H11511961 A JPH11511961 A JP H11511961A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- recombinant
- vaccinia
- alvac
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 44
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 title abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 287
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 129
- 230000002238 attenuated effect Effects 0.000 claims abstract description 33
- 231100000419 toxicity Toxicity 0.000 claims description 24
- 230000001988 toxicity Effects 0.000 claims description 24
- 230000001976 improved effect Effects 0.000 claims description 5
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 abstract description 79
- 238000000034 method Methods 0.000 abstract description 63
- 230000014509 gene expression Effects 0.000 abstract description 51
- 108091007433 antigens Proteins 0.000 abstract description 37
- 102000036639 antigens Human genes 0.000 abstract description 36
- 239000000427 antigen Substances 0.000 abstract description 35
- 210000000234 capsid Anatomy 0.000 abstract description 33
- 239000000523 sample Substances 0.000 abstract description 30
- 241000714201 Feline calicivirus Species 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 142
- 206010046865 Vaccinia virus infection Diseases 0.000 description 100
- 208000007089 vaccinia Diseases 0.000 description 100
- 238000011081 inoculation Methods 0.000 description 95
- 239000013612 plasmid Substances 0.000 description 95
- 241000699670 Mus sp. Species 0.000 description 92
- 241000700618 Vaccinia virus Species 0.000 description 76
- 229960005486 vaccine Drugs 0.000 description 73
- 238000012360 testing method Methods 0.000 description 67
- 239000013598 vector Substances 0.000 description 67
- 108020004414 DNA Proteins 0.000 description 62
- 206010037742 Rabies Diseases 0.000 description 61
- 238000012217 deletion Methods 0.000 description 61
- 239000012634 fragment Substances 0.000 description 61
- 230000037430 deletion Effects 0.000 description 60
- 239000000047 product Substances 0.000 description 57
- 241001465754 Metazoa Species 0.000 description 47
- 241000283973 Oryctolagus cuniculus Species 0.000 description 47
- 208000014674 injury Diseases 0.000 description 47
- 230000008733 trauma Effects 0.000 description 44
- 230000036039 immunity Effects 0.000 description 37
- 230000028993 immune response Effects 0.000 description 35
- 241000271566 Aves Species 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 30
- 230000006798 recombination Effects 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 28
- 230000010076 replication Effects 0.000 description 28
- 238000005215 recombination Methods 0.000 description 27
- 210000003501 vero cell Anatomy 0.000 description 27
- 230000001681 protective effect Effects 0.000 description 26
- 241000178270 Canarypox virus Species 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 108020004440 Thymidine kinase Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 21
- 108700026244 Open Reading Frames Proteins 0.000 description 21
- 108090000288 Glycoproteins Proteins 0.000 description 20
- 102000003886 Glycoproteins Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 19
- 241000282472 Canis lupus familiaris Species 0.000 description 18
- 101710154606 Hemagglutinin Proteins 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 18
- 101710176177 Protein A56 Proteins 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 17
- 108010005774 beta-Galactosidase Proteins 0.000 description 17
- 241000711798 Rabies lyssavirus Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 101150039990 B13R gene Proteins 0.000 description 15
- 101150060895 I4L gene Proteins 0.000 description 15
- 101150071286 SPI-2 gene Proteins 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 102000005936 beta-Galactosidase Human genes 0.000 description 15
- 238000010276 construction Methods 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 101150039660 HA gene Proteins 0.000 description 13
- 101100525041 Vaccinia virus (strain Western Reserve) VACWR073 gene Proteins 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 13
- 238000001114 immunoprecipitation Methods 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 108090000565 Capsid Proteins Proteins 0.000 description 12
- 102100023321 Ceruloplasmin Human genes 0.000 description 12
- 102000006601 Thymidine Kinase Human genes 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 230000002458 infectious effect Effects 0.000 description 12
- 238000007917 intracranial administration Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 244000144977 poultry Species 0.000 description 11
- 235000013594 poultry meat Nutrition 0.000 description 11
- 239000002356 single layer Substances 0.000 description 11
- 230000004543 DNA replication Effects 0.000 description 10
- 241000282560 Macaca mulatta Species 0.000 description 10
- 241000282695 Saimiri Species 0.000 description 10
- 210000005260 human cell Anatomy 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108091081024 Start codon Proteins 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000002008 hemorrhagic effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 241000287219 Serinus canaria Species 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 8
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000021186 dishes Nutrition 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108010017826 DNA Polymerase I Proteins 0.000 description 7
- 102000004594 DNA Polymerase I Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 7
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 7
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000000185 hemagglutinin Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 241000282579 Pan Species 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101150082239 G gene Proteins 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 108010046722 Thrombospondin 1 Proteins 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 230000036269 ulceration Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- -1 C 7L-K1L Proteins 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000724675 Hepatitis E virus Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 208000006339 Caliciviridae Infections Diseases 0.000 description 3
- 241000282552 Chlorocebus aethiops Species 0.000 description 3
- 241000700626 Cowpox virus Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010024769 Local reaction Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 206010058461 Orchitis noninfective Diseases 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108050008465 Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 3
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102100036034 Thrombospondin-1 Human genes 0.000 description 3
- 101100268528 Vaccinia virus (strain Copenhagen) A26L gene Proteins 0.000 description 3
- 101100268529 Vaccinia virus (strain Western Reserve) VACWR149 gene Proteins 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 108091008053 gene clusters Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000010284 hepatitis E Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 201000005737 orchitis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150068401 BSL1 gene Proteins 0.000 description 2
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 2
- 241000714198 Caliciviridae Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 101710172503 Chemokine-binding protein Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 101100049549 Enterobacteria phage P4 sid gene Proteins 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- GOZCEKPKECLKNO-RKQHYHRCSA-N Picein Chemical compound C1=CC(C(=O)C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GOZCEKPKECLKNO-RKQHYHRCSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710138270 PspA protein Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000282696 Saimiri sciureus Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 241000287231 Serinus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700646 Vaccinia virus WR Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 229940049155 rabies serum Drugs 0.000 description 2
- 229960003127 rabies vaccine Drugs 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 101150103863 sid gene Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001534961 Calicium Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000283987 Lepus capensis Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 101900272230 Vaccinia virus Core protein VP8 Proteins 0.000 description 1
- 241000881059 Vaccinia virus Wyeth Species 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ウイルスが弱毒化された毒性を有するが、効力は維持されるように不活化さ れたウイルスコード化遺伝子機能を有することを特徴とする修飾組換えウイルス 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/471,025 | 1995-06-06 | ||
US08/471,025 US5989561A (en) | 1991-03-07 | 1995-06-06 | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
PCT/IB1996/000721 WO1996039177A1 (en) | 1995-06-06 | 1996-06-03 | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006277710A Division JP2007082551A (ja) | 1995-06-06 | 2006-10-11 | 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11511961A true JPH11511961A (ja) | 1999-10-19 |
Family
ID=23869981
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9500280A Pending JPH11511961A (ja) | 1995-06-06 | 1996-06-03 | 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 |
JP2006277710A Pending JP2007082551A (ja) | 1995-06-06 | 2006-10-11 | 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006277710A Pending JP2007082551A (ja) | 1995-06-06 | 2006-10-11 | 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5989561A (ja) |
EP (1) | EP0831899B1 (ja) |
JP (2) | JPH11511961A (ja) |
AT (1) | ATE404219T1 (ja) |
AU (1) | AU721567B2 (ja) |
CA (1) | CA2223419A1 (ja) |
DE (1) | DE69637640D1 (ja) |
DK (1) | DK0831899T3 (ja) |
ES (1) | ES2313728T3 (ja) |
PT (1) | PT831899E (ja) |
WO (1) | WO1996039177A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
ATE181108T1 (de) * | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
EP0758397B1 (en) * | 1994-04-29 | 2005-06-22 | Baxter Healthcare S.A. | Recombinant poxviruses with foreign polynucleotides in essential regions |
FR2796397B1 (fr) * | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
FR2796396A1 (fr) * | 1999-07-16 | 2001-01-19 | Merial Sas | Gene de calicivirus felin et vaccin recombine les incorporant |
US6541458B1 (en) * | 1999-07-16 | 2003-04-01 | Merial | Feline calicivirus genes and vaccines in particular recombinant vaccines |
ES2192433B1 (es) * | 2000-09-01 | 2005-02-16 | Consejo Superior Investigaciones Cientificas | Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno. |
CA3063888C (en) | 2010-10-27 | 2020-12-22 | Dignity Health | Uterine electrical stimulation system and method |
ES2645156T3 (es) | 2011-03-21 | 2017-12-04 | Altimmune Inc. | Agente terapéutico inmunológico de acción rápida y prolongada |
CN112941036B (zh) * | 2021-02-08 | 2023-06-09 | 吉林惠康生物药业有限公司 | 一种提高狂犬病毒在人二倍体细胞中复制水平的方法 |
EP4380953A2 (en) * | 2021-08-05 | 2024-06-12 | VST LLC dba Medgene Labs | Rabbit haemorrhagic disease virus (rhdv) vaccines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522810A (en) * | 1982-12-09 | 1985-06-11 | The Regents Of The University Of California | Feline calicivirus vaccine |
JPH084508B2 (ja) * | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
EP0484382B1 (en) * | 1989-07-21 | 1995-03-08 | The Upjohn Company | Feline calicivirus capsid protein and nucleotide sequence |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
-
1995
- 1995-06-06 US US08/471,025 patent/US5989561A/en not_active Expired - Lifetime
-
1996
- 1996-06-03 PT PT96922179T patent/PT831899E/pt unknown
- 1996-06-03 AT AT96922179T patent/ATE404219T1/de active
- 1996-06-03 CA CA002223419A patent/CA2223419A1/en not_active Abandoned
- 1996-06-03 WO PCT/IB1996/000721 patent/WO1996039177A1/en active IP Right Grant
- 1996-06-03 ES ES96922179T patent/ES2313728T3/es not_active Expired - Lifetime
- 1996-06-03 DE DE69637640T patent/DE69637640D1/de not_active Expired - Lifetime
- 1996-06-03 DK DK96922179T patent/DK0831899T3/da active
- 1996-06-03 JP JP9500280A patent/JPH11511961A/ja active Pending
- 1996-06-03 EP EP96922179A patent/EP0831899B1/en not_active Expired - Lifetime
- 1996-06-03 AU AU63152/96A patent/AU721567B2/en not_active Expired
-
2006
- 2006-10-11 JP JP2006277710A patent/JP2007082551A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PT831899E (pt) | 2008-11-13 |
CA2223419A1 (en) | 1996-12-12 |
US5989561A (en) | 1999-11-23 |
AU6315296A (en) | 1996-12-24 |
DK0831899T3 (da) | 2008-10-27 |
EP0831899A1 (en) | 1998-04-01 |
WO1996039177A1 (en) | 1996-12-12 |
EP0831899A4 (en) | 2003-01-02 |
ATE404219T1 (de) | 2008-08-15 |
ES2313728T3 (es) | 2009-03-01 |
EP0831899B1 (en) | 2008-08-13 |
AU721567B2 (en) | 2000-07-06 |
DE69637640D1 (de) | 2008-09-25 |
JP2007082551A (ja) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4140862B2 (ja) | 組換体ポックスウイルス−狂犬病組成物および組合せ組成物並びに使用 | |
JP3940959B2 (ja) | 組換えポックスウイルス−サイトメガロウイルス組成物および使用 | |
US7144578B2 (en) | Poxvirus-rabies recombinants and compositions and methods employing the recombinants | |
JP4108742B2 (ja) | ポックスウイルス−イヌジステンパーウイルス(cdv)組み換え体類および組成物類および前記組み換え体類を用いる方法 | |
KR100242671B1 (ko) | 유전학적으로 처리한 백신 균주 | |
JP4138848B2 (ja) | 免疫不全組換えポックスウイルス | |
JP2007082551A (ja) | 組換えポックスウイルス−カリシウイルス[ウサギ出血疾患ウイルス(rhdv)]組成物および使用 | |
JPH09503902A (ja) | 組み換えウイルス免疫治療 | |
JP2007105040A (ja) | 組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法 | |
JP2007254489A (ja) | Htlv抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物 | |
JP3745370B2 (ja) | イヌヘルペスウイルスgB、gCおよびgDの、核酸およびアミノ酸配列とその利用 | |
WO1996039177A9 (en) | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses | |
CA2187207C (en) | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants | |
AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
AU6247000A (en) | Recombinant poxvirus-calicivirus (rabbit hemorrhagic disease virus (RHDV)) compositions and uses | |
AU1663601A (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof | |
AU4700096A (en) | Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060404 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060911 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060911 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060911 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061116 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20061221 |